Results from the PURE-01 trial show a durable 5-yr overall survival rate (77.4%) in muscle-invasive bladder cancer after neoadjuvant pembrolizumab and a correlation between pathological responses and survival outcomes. The claudin-low molecular subtype identifies patients especially responsive to immune checkpoint inhibitor monotherapy.
European Urology published a clinical update in Research Highlights on 02 Feb 2026.
The item focuses on Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
Review the original article for the full source wording and details.